A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Annals of Oncology

Volumn 7, Issue 4, 1996, Pages 347-353

  Rothenberg, M L ^a,b   Moore, M J ^c   Cripps, M C ^d   Andersen, J S ^e   Portenoy, R K ^f   Burris III, H A ^b,g   Green, M R ^h   Tarassoff, P G ^e   Brown, T D ⁱ   Casper, E S ^f   Storniolo, A M ^e   Von Hoff, D D ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e ELI LILLY AND COMPANY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g BROOKE ARMY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Clinical benefit; Gemcitabine; Pancreas; Quality of life

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PAIN ASSESSMENT; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 8944261362     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010600     Document Type: Article

References (17)

1. Ries LAG, Miller BA, Hankey BF et al. (eds). SEER Cancer Statistics Review, 1973-1991: Tables and Graphs, National Cancer Institute. NIH Pub. No. 94-2789. Bethesda, MD, 1994.
2. Howard JM, Jordan GL, Jr. Cancer of the pancreas. Curr Prob Cancer 1977; 2(3): 1-52.
3. Kelsen DP, Portenoy RK, Thaler HT et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13: 748-55.
4. Warshaw AW, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
5. Casper ES, Kelsen DP. Adenocarcinoma of the pancreas: Overview of workup and management. Adv Oncol 1995; 11: 17-22.
6. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6: 19-28.
7. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycytidine (Gemcitabine). Cancer Invest 1990; 8: 313-8.
8. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22.
9. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2′2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
10. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.
11. Fishman B, Pasternak S, Wallenstein SL et al. The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 1987; 60: 1151-8.
12. Heinemann V, Hertel LW, Grindey GB et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-31.
13. Xu Y-Z, Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1992; 44: 1819-27.
14. Heinemann V, Xu Y-Z, Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmcol 1990; 38: 567-72.
15. Ruiz van Haperen VWT, Veerman G, Vermerken JB et al. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993; 46: 762-6.
16. O'Shaughnessy JA, Wittes RE, Burke G et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 1991; 9: 2225-32.
17. Moore M, Andersen J, Burris H et al. A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 1995; 14: 199 (Abstr # 473).